Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: Practical clinical management questions

Clinical Transplantation

Volumn 25, Issue 5, 2011, Pages

  Epailly, E ^a   Albanell, J ^b   Andreassen, A ^c   Bara, C ^d   Campistol, J M ^e   Delgado, J F ^f   Eisen, H ^g   Fiane, A E ^h   Mohacsi, P ⁱ   Schubert, S ^j   Sebbag, L ^k   Turazza, F M ^l   Valantine, H ^m   Zuckermann, A ⁿ   Potena, L ^o  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ BERN UNIVERSITY HOSPITAL   (Switzerland)

^j DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^k HOSPICES CIVILS DE LYON   (France)

^l OSPEDALE NIGUARDA CA GRANDA   (Italy)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Everolimus; Heart transplantation; Immunosuppression; Malignancy; Proliferation signal inhibitors

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPSTEIN BARR VIRUS; FAMILY HISTORY; HEART TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; METASTASIS; MONOTHERAPY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; ONCOVIRINAE; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; POSTTRANSPLANT MALIGNANCY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SKIN CANCER; T LYMPHOCYTE ACTIVATION; TUBEROUS SCLEROSIS; TUMOR GROWTH; VIRUS ACTIVATION; WOUND HEALING DELAY;

CELL PROLIFERATION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; POSTOPERATIVE COMPLICATIONS;

EID: 80054122390     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01476.x     Document Type: Review

References (119)

1. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009: 28: 1007.
2. NIH. (accessed February 3, 2010).
3. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007: 67: 1167.
4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004: 4: 222.
5. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006: 19: 607.
6. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
7. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004: 18: 446.
8. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006: 25: 1186.
9. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2years: a randomized clinical trial. Circulation 2004: 110: 2694.
10. Guba M, Von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
11. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999: 397: 530.
12. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005: 80: 1233.
13. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351: 623.
14. Tremblay F, Fernandes M, Habbab F et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2002: 9: 785.
15. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005: 352: 1371.
16. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol 2004: 11: 141.
17. Swann PF, Waters TR, Moulton DC et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996: 273: 1109.
18. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005: 309: 1871.
19. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998: 66: 507.
20. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005: 24: 517.
21. David KM, Morris JA, Steffen BJ et al. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005: 19: 279.
22. Dumortier J, Gagnieu MC, Salandre J et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006: 12: 1342.
23. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001: 24: 645.
24. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005: 1: 505.
25. Arslan H, Inci EK, Azap OK et al. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 2007: 9: 270.
26. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996: 15: 435.
27. Khush KK, Valantine HA. New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs 2009: 14: 1.
28. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990: 323: 1723.
29. Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? Nat Clin Pract Cardiovasc Med 2006: 3: 203.
30. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003: 349: 847.
31. Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009: 22: 78.
32. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
33. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005: 352: 1317.
34. Koehl G, Schlitt H, Geissler E. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplant Rev 2005: 19: 20.
35. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007: 22(Suppl 1): i4.
36. Crespo-Leiro MG, Alonso-Pulpon L, Arizon JM et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. J Heart Lung Transplant 2007: 26: 1105.
37. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004: 4: 905.
38. Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 2009: 87: S19.
39. Delgado JF, Crespo MG, Pulpon LA et al. Pre-existing neoplasms and risk for malignancy after heart transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry. J Heart Lung Transplant 2007: 26: S124.
40. Fricker FJ, Addonizio L, Bernstein D et al. Heart transplantation in children: indications. Report of the Ad Hoc Subcommittee of the Pediatric Committee of the American Society of Transplantation (AST). Pediatr Transplant 1999: 3: 333.
41. Wendler O, Schäfers H-J. Malignancy After Heart and Lung Transplantation. Basel: Contrib Oncol, 2000: 13.
42. Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006: 25: 1024.
43. Chen PL, Chang HH, Chen IM et al. Malignancy after heart transplantation. J Chin Med Assoc 2009: 72: 588.
44. Schubert S, Renner C, Hammer M et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008: 27: 100.
45. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005: 51: 494.
46. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004: 64: 252.
47. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003: 75: 1710.
48. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002: 73: 1565.
49. Doesch AO, Muller S, Konstandin M et al. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc 2010: 42: 3694.
50. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008: 8: 2212.
51. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006: 22: 159.
52. Huang S, Houghton PJ. Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev 2001: 20: 69.
53. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004: 77: 1319.
54. Hu X, Pandolfi PP, Li Y et al. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005: 7: 356.
55. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010: 10: 571.
56. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003: 102: 972.
57. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010: 29: 3733.
58. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004: 77: 760.
59. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007: 26: 557.
60. Groetzner J, Kaczmarek I, Meiser B et al. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. J Heart Lung Transplant 2004: 23: 770.
61. Hunt J, Lerman M, Magee MJ et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005: 24: 1863.
62. Groetzner J, Kaczmarek I, Landwehr P et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004: 25: 333.
63. Groetzner J, Meiser B, Landwehr P et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004: 77: 568.
64. Potena L, Bianchi IG, Magnani G et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010: 89: 263.
65. Gullestad L, Iversen M, Mortensen SA et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010: 89: 864.
66. Gullestad L, Mortensen SA, Eiskjaer H et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010: 90: 1581.
67. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003: 108: 48.
68. Ankersmit HJ, Roth G, Zuckermann A et al. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. Am J Transplant 2003: 3: 231.
69. Salgo R, Gossmann J, Schofer H et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010: 10: 1385.
70. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007: 13: 433.
71. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007: 9: 484.
72. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007: 26: 611.
73. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007: 22(Suppl 1): i17.
74. Lebbe C, Euvrard S, Barrou B et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006: 6: 2164.
75. Fernandez A, Marcen R, Pascual J et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006: 38: 2453.
76. De Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007: 22(Suppl 1): i23.
77. Euvrard S, Boissonnat P, Roussoulieres A et al. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients. Transpl Int 2010: 23: 855. Epub 2009 Nov 27
78. Signorell J, Hunziker T, Martinelli M, Koestner S, Mohacsi PJ. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from CNI-based immunosuppression in a cardiac transplant recipient. Transplant Proc 2010: 42: 3871.
79. Chen J, Ruczinski I, Jorgensen TJ et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008: 100: 1215.
80. Stippel DL, Kasper HU, Schleimer K et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005: 37: 2185.
81. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005: 79: 855.
82. Tabernero J, Rojo F, Burris H et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol 2005: 23: 3007.
83. Boulay A, Stephan C, Zumstein-Mecker S. Phospho-Akt levels as a potential biomarker of in vitro sensitivity of tumor cell lines to the mTOR pathway inhibitor RAD001. Clin Cancer Res 2003: 9: B170.
84. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008: 372: 449.
85. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008: 44: 84.
86. Haritunians T, Mori A, O'Kelly J et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007: 21: 333.
87. Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007: 25: 4806.
88. Gomez-Camarero J, Salcedo M, Rincon D et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007: 84: 786.
89. Ruiz JC, Sanchez A, Rengel M et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 2007: 39: 2157.
90. Jundt F, Raetzel N, Muller C et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005: 106: 1801.
91. Zitzmann K, De Toni EN, Brand S et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007: 85: 54.
92. Mabuchi S, Altomare DA, Cheung M et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007: 13: 4261.
93. Chiurchiu C, Carreno CA, Schiavelli R et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 2010: 42: 277.
94. Manito N, Delgado JF, Crespo-Leiro MG et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010: 24: 129.
95. Kuppahally S, Al-Khaldi A, Weisshaar D et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006: 6: 986.
96. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869.
97. Tenderich G, Fuchs U, Zittermann A et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007: 21: 536.
98. Aliabadi AZ, Mahr S, Dunkler D et al. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008: 86: 1771.
99. Magnani G, Almenar L, Vigano M et al. Changes in lipid profiles associated with everolimus- and MMF-based immunosuppression are clinically comparable in de novo cardiac transplant recipients. J Heart Lung Transplant 2009: 28: S90.
100. Raichlin E, Khalpey Z, Kremers W et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007: 84: 467.
101. Aliabadi AZ, Pohanka E, Seebacher G et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008: 8: 854.
102. Oroszlan M, Bieri M, Ligeti N et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010: 23: 125.
103. Otley CC, Berg D, Ulrich C et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006: 154: 395.
104. Patel J, Kobashigawa JA. Minimization of immunosuppression: transplant immunology. Transpl Immunol 2008: 20: 48.
105. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006: 82: 663.
106. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006: 6: 150.
107. Groetzner J, Kaczmarek I, Schulz U et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009: 87: 726.
108. Raichlin E, Bae JH, Khalpey Z et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007: 116: 2726.
109. Pham MX, Teuteberg JJ, Kfoury AG et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010: 362: 1890.
110. Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther 2006: 19: 306.
111. Gold PJ, Iriarte D, Arthur J, Kaplan H. Phase II trial of RAD001 in patients with refractory metastatic colorectal cancer. Abstract - No. 513 2008 Gastrointestinal Cancers Symposium - Category: Colon and Rectum - Multidisciplinary Treatment.
112. Sandrini S, Setti G, Bossini N, Maiorca P. [Cancer after kidney transplantation]. G Ital Nefrol 2004: 21(Suppl 26): S67.
113. Cherikh WS, Kauffman HM, McBride MA et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289.
114. Starling RC, Hare JM, Hauptman P et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004: 4: 2126.
115. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001: 40: 573.
116. Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transplant 2002: 21: 493.
117. Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005: 80: 157.
118. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007: 21: 149.
119. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006: 108: 2942.